sponsored
PatientsVille.com Logo

PatientsVille

Pi3k Medical Research Studies

Up-to-date List of Pi3k Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pi3k Medical Research Studies

Rank Status Study
1 Unknown  Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT
Condition: Left Ventricular Dyssynchrony
Intervention: Device: 3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)
Outcome Measures: Left ventricular phase standard deviation.;   Left ventricular entropy;   Left ventricle ejection fraction;   Quality of life.;   6-minutes walking test
2 Recruiting Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum
Conditions: Left Ventricular Dysfunction;   Cardiac Conduction Defect;   Heart Failure;   Sick Sinus Syndrome
Intervention: Device: Left ventricular septum pacing lead
Outcome Measures: Number of successful LV septum lead implantations;   Change in sensing values, pacing threshold and lead impedance;   Number of participants with procedure or lead related adverse events;   Acute change in LVdP/dtmax;   Acute change in LV stroke volume;   Acute change in QRS duration;   Acute change in 3-dimensional QRS vector direction;   Acute change in SPECKLE-tracking strain;   Difference between relative changes in LV stroke volume assessed by Nexfin and relative changes in invasively measured LVdp/dtmax.
3 Recruiting Left Ventricular Pacing to Avoid Cardiac Enlargement Study
Conditions: Complete AV Block;   Sick Sinus Syndrome
Interventions: Device: LV pacing;   Device: RV pacing
Outcome Measures: Left Ventricular ejection fraction (%) at 12 months;   Left Ventricular end-systolic volume (ml) at 12 months;   Left Ventricular end-diastolic volume (ml) at 12 months;   NYHA functional class;   Functional capacity;   Quality of life;   NT-proBNP
4 Not yet recruiting Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads
Condition: Heart Failure
Intervention: Device: Sentus QP left ventricular lead
Outcome Measures: Sentus QP related complication-free rate through 6 months;   Percentage of patients with acceptable pacing threshold of Sentus QP lead in permanently programmed vector at 3 months;   Sentus QP pacing threshold in permanently programmed vector at 3 months per lead model;   Sentus QP pacing threshold in novel vectors at 3 months;   Sentus QP R-wave sensed amplitude at 3 months per lead model;   Sentus QP pacing impedance at 3 months per lead model;   Sentus QP Time to first complication
5 Recruiting Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure
Conditions: Left Ventricular Dysfunction;   Heart Failure
Interventions: Device: biventricular pacemaker with epicardial Left Ventricular lead;   Device: transvenous Left Ventricular lead placement
Outcome Measures: Degree of change in cardiac perfusion following epicardial LV lead placement, compared to transvenous LV lead placement;   Resynchronization of the LV, measured with TDI, 2D- and 3D-echocardiography, in patients with epicardial LV lead placement, compared to transvenous LV lead placement
6 Not yet recruiting MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease
Conditions: Left Ventricular Hypertrophy;   Insulin Resistance;   Coronary Artery Disease
Interventions: Drug: Metformin XR;   Drug: Placebo
Outcome Measures: Left Ventricular Mass Index;   Central and Abdominal obesity;   Left Ventricular end systolic volume,;   Endothelial Function;   Insulin Resistance;   Inflammatory and other cardiovascular blood markers;   Number of participants with Adverse Event;   Left Ventricularend diastolic volume;   Left Ventricular Ejection Fraction
7 Recruiting Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias
Conditions: Bradyarrhythmias;   Arrhythmias;   Atrioventricular Block;   Ventricular Dysfunction;   Cardiovascular Disease
Interventions: Device: Left Ventricular pacing through coronary sinus tributaries (Attain StarFix);   Device: Right ventricular pacing (Medtronic)
Outcome Measures: Surgical success;   Echocardiographic and Clinical composite
8 Recruiting Effects of Intensive Statin Treatment on Left Ventricular Function
Condition: Acute Anterior Myocardial Infarction
Interventions: Drug: standard group;   Drug: intensive group
Outcome Measures: left ventricular function;   the left ventricular function;   plasma brain natriuretic peptide
9 Recruiting New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function
Condition: Cardiovascular Pathology
Intervention:
Outcome Measures: Left Ventricular longitudinal systolic strain (LV-LSS) in all patients;   mitral annular plane systolic excursion (MAPSE) in all patients;   mitral annular systolic velocity (MASV) in all patients;   diastolic Left Ventricular function in all patients;   pulmonary artery systolic pressure (PASP) in all patients;   Left Ventricular ejection fraction (LVEF) in all patients
10 Unknown  Evaluation of Radial Strain for Assessment of Left Ventricular Function in Transesophageal Echocardiography
Condition: Ventricular Function, Left
Intervention: Procedure: TEE (transesophageal echocardiography)
Outcome Measures: left ventricular function;   Left Ventricular function during changes in loading conditions
11 Recruiting Left Ventricular MultiSpot Pacing for CRT (iSPOT)
Condition: Heart Failure
Interventions: Device: MultiSpot pacing;   Device: MultiVein pacing;   Device: Standard biventricular pacing
Outcome Measures: Change in positive Left Ventricular (LV) dP/dt max (mm HG/sec) of multispot LV pacing configuration compared to normal biventricular pacing;   Change in positive Left Ventricular (LV) dP/dt max (mm HG/sec) of multi-vein LV pacing configuration compared to normal biventricular pacing;   Change in positive Left Ventricular (LV) dP/dt max (mm HG/sec) of multi-vein LV pacing configuration compared to multispot LV pacing configuration;   Correlation of blood pressure, EGMs and electrocardiographic mapping measurements with the positive LV dP/dt max values;   Use of non-invasive measurements to identify pacing configuration with highest positive LV dP/dt max;   Within patient variability in positive LV dP/dt max
12 Recruiting Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease
Condition: Left Ventriclar Mass
Interventions: Drug: Metformin;   Drug: placebo
Outcome Measures: Left ventricular mass.;   Left ventricular volume and endothelial function.
13 Unknown  Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
Conditions: Myocardial Reperfusion Injury;   Cardiac Output, Low;   Hypertrophy, Left Ventricular
Interventions: Drug: Perhexiline;   Drug: Placebo marked PEXSIG
Outcome Measures: Absolute difference in Cardiac Index (>0.3 l/min/m2);   Incidence of Low Cardiac Output Syndrome;   Incidence of inotrope use according to protocol;   Peak and total release of Troponin
14 Unknown  Role of Left Ventricular Pacing Site
Conditions: Heart Failure;   Cardiomyopathy, Dilated;   Coronary Disease
Intervention: Device: left ventricular pacing
Outcome Measures: Variation in left ventricular dp/dt max;   pressures and volumes of the left ventricle;   stroke work;   surface ECG repolarisation
15 Recruiting Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
Condition: Hypertensive Left Ventricular Hypertrophy
Interventions: Drug: Aliskiren;   Drug: Eplerenone
Outcome Measures: reduction of Left Ventricular hypertrophy measured by magnetic resonance imaging;   Cardiovascular events
16 Unknown  Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Conditions: Acromegaly;   Heart Failure;   Hypertrophy, Left Ventricular
Intervention: Drug: pegvisomant
Outcome Measures: Change in peak systolic strain rate (SRSYS) determined by Color Doppler Myocardial Imaging (CDMI).;   Ejection fraction,Enddiastolic thickness of the infero-lateral wall,Diastolic function,Left Ventricular mass index,Stroke volume,Ejection fraction (MRI),CO,Late hyperenhancement,IGF-I,insulin sensitivity,Ringsize,adverse events,Endothelial function
17 Recruiting Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients
Condition: End Stage Renal Disease
Intervention:
Outcome Measures: Coronary Artery Calcification;   Left ventricular mass;   All cause mortality;   Left ventricular hypertrophy
18 Recruiting Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.
Conditions: Heart Failure;   Ischemic Cardiomyopathy
Intervention: Biological: Allogeneic stem cells implantation
Outcome Measures: Improvement in myocardial perfusion/viability;   all-cause morbidity;   left ventricular function;   all-cause mortality
19 Recruiting Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Conditions: Type 2 Diabetes;   Coronary Artery Disease;   Left Ventricular Mass
Intervention: Drug: alpha-lipoic acid
Outcome Measures: Alpha-lipoic acid regress the Left Ventricular mass;   The change of endothelial dysfunction before and after alpha-lipoic acid intervention.
20 Recruiting REVADE : Right Ventricular Function and Exercise in Left Ventricular Assist Device Patients : Echocardiographic Study
Condition: Left Ventricular Assist Devices Patients
Intervention: Other: adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography
Outcome Measures: assessment of right chambers dimensions for the evaluation of right ventricular function;   assessment of RV strain for the evaluation of right ventricular function;   assessment of RV shortening fraction for the evaluation of right ventricular function;   assessment of TAPSE for the Evaluation of right ventricular function;   assessment of RV fractional Area change for the evaluation of right ventricular function;   assessment of Tricuspid annulus tissue doppler imaging for the evaluation of right ventricular function;   Tricuspid regurgitation analysis for the evaluation of right ventricular function;   pulmonary pressures analysis for the evaluation of right ventricular function;   Assessment of RV strain rate for the evaluation of right ventricular function;   peak oxygen consumption (VO2 max) as a functional evaluation of VO2 max on exercise;   quality of life scores as an assessment of quality of life;   BNP levels as an assessment of BNP levels;   Blood pressure monitoring as an assessment of blood pressure

These studies may lead to new treatments and are adding insight into Pi3k etiology and treatment.

A major focus of Pi3k research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Pi3k